# Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

> **NCT00082810** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer
- Recurrent Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** fulvestrant
- **DRUG:** tipifarnib

## Key facts

- **NCT ID:** NCT00082810
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082810, "Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00082810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*